NOROMBY HP SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

ENOXAPARIN SODIUM

Inapatikana kutoka:

JUNO PHARMACEUTICALS CORP.

ATC kanuni:

B01AB05

INN (Jina la Kimataifa):

ENOXAPARIN

Kipimo:

150MG

Dawa fomu:

SOLUTION

Tungo:

ENOXAPARIN SODIUM 150MG

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Prescription

Eneo la matibabu:

HEPARINS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0131860002; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2020-10-14

Tabia za bidhaa

_ _
_NOROMBY _
_Page 1 of 78_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
NOROMBY
TM
Enoxaparin sodium
Solution for injection, 100 mg/mL
BP
20 mg/0.2 mL
30 mg/0.3 mL
40 mg/0.4 mL
60 mg/0.6 mL
80 mg/0.8 mL
100 mg/mL
(Subcutaneous or Intravenous Use Only)
Pr
NOROMBY
TM HP
Enoxaparin sodium
Solution for injection, 150 mg/mL
BP
120 mg/0.8 mL
150 mg/mL
(Subcutaneous or Intravenous Use Only)
ATC Code: B01AB05
Anticoagulant/Antithrombotic Agent
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, Ontario
L5N 2X7
Date of Initial Approval:
October 14, 2020
Date of Revision:
February 12, 2021
Submission Control No: 233058
_ _
_NOROMBY _
_Page 2 of 78_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................4
1
INDICATIONS
..............................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics
............................................................................................................4
2
CONTRAINDICATIONS................................................................................................4
3
DOSAGE AND
ADMINISTRATION...............................................................................5
3.1
Dosing
Considerations.........................................................................................5
3.2
Recommended Dose and Dosage Adjustment
.....................................................5
3.3
Administration
.....................................................................................................8
3.4
Missed Dose
.....................................................................................................10
4
OVERDOSAGE
..........................................................................................................10
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND
PACKAGING................